MediciNova, Inc.  

(Public, NASDAQ:MNOV)   Watch this stock  
Find more results for MNOV
7.01
-0.03 (-0.43%)
After Hours: 7.01 0.00 (0.00%)
Dec 2, 4:38PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.96 - 7.16
52 week 3.20 - 10.16
Open 7.03
Vol / Avg. 31,800.00/60,580.00
Mkt cap 240.73M
P/E     -
Div/yield     -
EPS -0.38
Shares 34.49M
Beta 0.80
Inst. own 22%

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -27.36% -27.14%
Return on average equity -31.11% -32.31%
Employees 10 -
CDP Score - -

Address

4275 Executive Sq Ste 650
LA JOLLA, CA 92037-1477
United States - Map
+1-858-3731500 (Phone)
+1-858-4040048 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

MediciNova, Inc. is a biopharmaceutical company. The Company is focused on acquiring and developing small molecule therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States market. It is focused on its development activities on MN-166 (ibudilast) for neurological disorders and MN-001 (tipelukast) for fibrotic diseases, such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). Its pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers. Its MN-166 is an oral, anti-inflammatory and neuroprotective agent, which inhibits macrophage migration inhibitory factor (MIF) and certain phosphodiesterases (PDEs). Its MN-001 is an orally bioavailable small molecule compound. Its MN-221 is a highly selective B2-adrenergic receptor agonist being developed for the treatment of acute exacerbations of asthma.

Officers and directors

Jeffrey Himawan Ph.D. Independent Chairman of the Board
Age: 51
Bio & Compensation  - Reuters
Yuichi Iwaki M.D., Ph.D. President, Chief Executive Officer, Director
Age: 65
Bio & Compensation  - Reuters
Ryan Selhorn Chief Financial Officer
Bio & Compensation  - Reuters
Geoffrey G. O'Brien J.D. Vice President
Age: 46
Bio & Compensation  - Reuters
Masatsune Okajima Vice President, Head - Japanese Office
Age: 47
Bio & Compensation  - Reuters
Kazuko Matsuda M.D., Ph.D. Chief Medical Officer
Age: 48
Bio & Compensation  - Reuters
Yoshio Ishizaka Independent Director
Age: 75
Bio & Compensation  - Reuters
Yutaka Kobayashi Independent Director
Age: 51
Bio & Compensation  - Reuters